Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts less than Nifty Midcap 150 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alkem Laboratories reported consolidated revenue from operations of ₹37,368 Mn for Q3 FY26, up 10.7% year-on-year, with international sales growing strongly at 26.6%. EBITDA was ₹8,280 Mn (margin 22.2%, slightly down from 22.5% in Q3 FY25), and profit after tax stood at ₹6,360 Mn, up just 1.6% YoY due to a ₹528 Mn exceptional charge related to the newly notified Labour Codes. For the nine months ended December 2025, revenue grew 13.1% YoY to ₹111,090 Mn and PAT rose 11.1% to ₹20,653 Mn. The Board declared an interim dividend of ₹43 per share (2,150% on face value), with a record date of 20 February 2026. The company also announced a binding term sheet to acquire a majority stake in Switzerland-based Occlutech Holding AG, a cardiac implants maker, through its medtech subsidiary.
Stable topline growth with continued strength in international markets, particularly the US (18.8% YoY) and non-US geographies (41.6% YoY), supports the growth narrative, though the one-time Labour Code charge and slight EBITDA margin compression may temper near-term PAT growth. The generous interim dividend and strategic medtech acquisition via Occlutech are positives for shareholders.